INTRODUCTION {#sec1-1}
============

Moderate sedation is a drug-induced depression of consciousness during which a patient responds purposefully to verbal commands. This level of sedation implies an interactive state, depending on the patient\'s age. With moderate sedation, no intervention is required to maintain a patent airway, adequate and spontaneous ventilation. Cardiovascular function is usually maintained.\[[@ref1]\]

Moderate sedation can be applied for different types of pediatric procedures such as bone marrow aspiration (BMA), lumbar puncture (LP), and endoscopic procedures.\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\]

Patients who are American Society of Anesthesiologists (ASA) Class I and II \[[Table 1](#T1){ref-type="table"}\] are considered appropriate candidates for moderate sedation; children in ASA Class III and IV or children with special needs and those with anatomic airway abnormalities will usually be referred to anesthesiologist.\[[@ref1]\]

###### 

American Society of Anesthesiologists physical status classification
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Ketamine is one of the medications, which is used commonly for moderate sedation in pediatrics.

Previous studies evaluated moderate sedation for pediatric procedure in emergency department.\[[@ref2][@ref3][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]\] However, pediatric moderate sedation unit is uncommon. Godoy *et al*.\'s study is one of the few studies, which evaluated the moderate sedation in pediatric critical care unit.\[[@ref14]\]

Many medications used in moderate sedation include ketamine, midazolam, fentanyl, propofol, nitrous oxide, or etomidate.\[[@ref13][@ref15]\]

Ketamine is a desirable agent because of its good pain control with minimum side effects.

The focus will be on ketamine use in moderate sedation. Ketamine is one of the medications, which has been used increasingly and commonly since 1970 in moderate sedation. Ketamine is nonbarbiturate phencyclidine derivative dissociative agent, with sedative, hypnotic, analgesic, amnestic properties, relative preservation of airway tone, cardiovascular stability, and maintenance of spontaneous respiration.\[[@ref7][@ref8]\]

Mechanism of action depends on N-methyl-D-aspartate glutamate receptor antagonism; it undergoes hepatic metabolism to norketamine, which is also analgesic agent, and has approximately one-third of the activity of ketamine itself. Further, norketamine undergoes urinary excretion.\[[@ref8][@ref15]\] Ketamine clearance increases with decreasing age.\[[@ref8][@ref13]\]

In our Pediatric Intensive Care Unit (PICU), pediatric intensivist is usually responsible for daily session of moderate sedation for different types of pediatric procedures such as BMA, LP, and gastro-endoscope. In this study, the moderate sedation in PICU settings, its safety, and efficacy were reviewed.

MATERIALS AND METHODS {#sec1-2}
=====================

Objectives {#sec2-1}
----------

To review moderate sedation in PICU settings, its safety, and efficacy using ketamine and midazolam which will provide more experience and support about future independent moderate sedation unit.

Inclusion criteria {#sec2-2}
------------------

Both male and female patientsAge 1 month to 14 yearsASA I: Healthy patient or ASA IINothing by mouth (NPO) for the last 6 h.

Exclusion criteria {#sec2-3}
------------------

Intubated patientsPatients who had moderate sedation by other sedative drugs (e.g., propofol, dexmedetomidine).

Outcomes {#sec2-4}
--------

### Primary outcome {#sec3-1}

To evaluate the safety and efficacy of moderate sedation in PICU settings using ketamine and midazolam.

### Secondary outcome {#sec3-2}

To identify categories of diseases for whom underwent for moderate sedationTo review ketamine doses given for procedural sedationTo identify moderate sedation-related adverse events.

Definitions {#sec2-5}
-----------

Optimal moderate sedation: Drug-induced depression of consciousness during which a patient responds purposefully to verbal commands (e.g., "open your eyes") either alone or accompanied by light tactile stimulation, such as a light tap on the shoulder or face, not a sternal rub. With moderate sedation, no intervention is required to maintain a patent airway, adequate and spontaneous ventilation. Cardiovascular function is usually maintained\[[@ref8]\]Optimal ketamine dose (as described in sedation protocol): 1--1.5 mg/kg\[[@ref2][@ref5]\]Adverse events to moderate sedation: Unwanted and usually harmful events, moderate sedation-related, such as hypotension, bradycardia, stridor, or hypoxemia.\[[@ref2][@ref5]\]

Study design {#sec2-6}
------------

This is a retrospective, by charts review, which was conducted in the PICU. The study started after Research Office\'s approval. The patients who had received moderate sedation during 2011, as we had approved and are eligible to inclusion criteria, were included in the study.

Data collection {#sec2-7}
---------------

Patients had come from pediatric wards to the PICU for procedural sedation only. After the procedure, they stayed in PICU until appropriate discharge criteria \[[Table 2](#T2){ref-type="table"}\].

###### 

Recommended discharge criteria
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Moderate sedation was managed by pediatric intensivist, pediatric intensive care nurse, according to moderate sedation protocol in our institution. This protocol includes preassessment \[[Table 1](#T1){ref-type="table"}\], vital signs monitoring, discharge criteria, and medications. These moderate sedation medications consist of ketamine (1--1.5 mg/kg), midazolam (0.1--0.05 mg/kg), and atropine. For each moderate sedation session, a sedation record sheet was filled and completed before the procedure, together with the informed consent. During the procedure, the following data were monitored and recorded every 5 min: Vital signs (heart rate, respiratory rate, O~2~ saturation, blood pressure), oxygen requirement, administered drugs, and associated adverse events.

All patients received supplemental oxygen with nasal cannula during sedation.

Analysis of the data included demographic details (age, gender) weight, procedure(s) performed, doses of each medication per kilogram body weight, and adverse effects.

RESULTS {#sec1-3}
=======

A total of 253 moderate sedation sessions were performed over the study period (2011). Seven patients were excluded from the study because of incomplete moderate sedation sheet data.

All of the 246 patients who had moderate sedation and received ketamine were included in the study. Some patients required extra doses, especially ketamine (71.4% for ketamine), during the procedure.

There were 59.8% (*n* = 147) males and 40.2% (*n* = 99) females, infant 5.3% (*n* = 13), and children (1--14 years) 94.7% (*n* = 233). Majority of procedures were LP 65.3% (*n* = 160).

Regarding diseases nature, the most common was hematology-oncology disease 80.89% (*n* = 199), followed by gastrointestinal disease 10.16% (*n* = 25) and neurological disease 8.94% (*n* = 22). Details are shown in Tables [3](#T3){ref-type="table"}--[5](#T5){ref-type="table"}.

###### 

Age, *n* (%)
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###### 

Type of procedure, *n* (%)
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###### 

Disease type, *n* (%)
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Most of the patients received two doses of ketamine or more (ketamine dose 1--1.5 mg/kg) (71.4%) \[[Table 6](#T6){ref-type="table"}\]. We could not obtain enough data to evaluate the ketamine doses number relation to the procedure type or duration of moderate sedation session.

###### 

Number of ketamine doses received (*n*=246)
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In midazolam side, most of the patients received only one dose of midazolam 77.2% (*n* = 190) as shown in [Table 7](#T7){ref-type="table"}. Three patients were sedated with only ketamine, and they did not receive midazolam. Only 22.8% of patients received more than one dose of midazolam to achieve good sedation \[[Table 7](#T7){ref-type="table"}\].

###### 

Number of midazolam doses received (*n*=246)
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Patients have multiple visits (repeated procedures). The patients have been sedated either by giving them a single dose or multiple doses of ketamine. Each dose was assumed as an episode; hence, the total number of episodes is 515 for ketamine.

Most patients 87.37% (*n* = 450) received the ketamine within the recommended dosage (1--1.5 mg/kg) according to the protocol, while 12.62% (*n* = 65) of them received less than recommended dose of ketamine \[[Table 8](#T8){ref-type="table"}\].

###### 

Ketamine doses (*n*=515)
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The patients have been given a supplemental midazolam single dose or multiple doses. Each dose was assumed as an episode; hence, the total number of episodes is 306 for midazolam.

The majority 96.08% (*n* = 294) of the patients received regular doses of midazolam; only 3.92% (*n* = 12) of them received either suboptimal or exceeded doses \[[Table 9](#T9){ref-type="table"}\].

###### 

Midazolam doses (*n*=306)
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Adverse events including apnea, laryngeal spasm, hypotension, and recovery agitation were observed during moderate sedation. It has been noticed in four sessions, i.e., 1.6%, which includes hypoxia, laryngeal spasm, and hypotension, while we did not notice recovery agitation in our patients \[[Table 10](#T10){ref-type="table"}\], all of it were mild to moderate and managed conservatively.

###### 

Distribution of adverse events
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DISCUSSION {#sec1-4}
==========

Ketamine dose was studied by a lot of research.\[[@ref7][@ref10]\] The studies compare administration of initial dose 1 mg/kg intravenous (IV), with 1.5 mg/kg IV. Dose of 1 mg/kg IV is suitable for short procedure which is \<5 min because 90% of them will have \<0.75 mg/L at 10 min of administration, while the dose of 1.5 mg/kg IV seems to be suitable more for longer procedure because 50% of those who received 1.5 mg/kg IV have \<0.75 mg/L at 10 min and no cardiopulmonary effects were noted with either doses.\[[@ref7][@ref10]\]

In another randomized, double-blind clinical trials, midazolam combined with ketamine did not reduce recovery agitation and other side effects related to ketamine sedation, and its use appears unnecessary.\[[@ref16]\]

Most (108) 44.1% of our patients received two doses of ketamine; the number of ketamine doses differs from one patient to another and also relates to type of procedure. Some of the patients have multiple exposure to moderate sedation, which may play a role in the number of ketamine doses, which could not be investigated in our patients.

Some of our patients received less than the recommended dose of ketamine. Again, this may increase the dose frequency of ketamine, but different types of procedures and different number of exposure may affect the results.

In relation to moderate sedation\'s safety, the side effects encountered were minimal. All of them occurred with patients who received optimal doses of ketamine and midazolam. All patients responded quickly to the appropriate management; hypoxemia episodes and laryngeal spasm were managed by supplying oxygen, positioning, and secretion suction. Advanced airway was not required.

This study evaluates protocol-based moderate sedation procedure in PICU and by pediatric intensivist. In conclusion, results of our analysis showed that most of our patients required more than one dose of ketamine (71.4%) plus a dose of midazolam to achieve moderate sedation, with minimum side effects. This suggests that moderate sedation sessions in PICU are safe for different types of procedures such as LP, BMA, endoscopy, and colonoscopy.

The timing and the type of procedures in relation to dosages of ketamine were not examined because of the different types of procedures and different times of exposure to moderate sedation sessions, and this can be considered as a limitation of this review.

Financial support and sponsorship {#sec2-8}
---------------------------------

Nil.

Conflicts of interest {#sec2-9}
---------------------

There are no conflicts of interest.
